Rules/misleading presentation/US-MIS-041

A deceptive net impression can be misleading even when individual claims are not

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

A promotional communication that conveys a deceptive net impression of the product could be misleading even if its specific individual claims or presentations are not misleading; the piece should be evaluated as a whole, not claim by claim, for whether it conveys an accurate and non-misleading impression of the product's benefits and risks.

Check

Read the piece as a whole (all text, visuals, audio, layout) the way a reasonable audience member would, and assess whether the combined impression overstates benefit or understates risk relative to what the individual statements say.

Escalate when

Any time individual claims pass review in isolation but the overall impression is debatable.

Where this comes from

Section II.B, Policy Overview · page 7. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…atements, but at the net impression – i.e., the message communicated by all elements of the piece as a whole. The purpose of the evaluation is to determine whether the piece as a whole conveys an accurate and non-misleading impression of the benefits and risks of the promoted product. Manufacturers should therefore focus not just on individual claims or presentations, but on the promotional piece as a whole. A promotional communication that conveys a deceptive net impression of the product could be misleading, even if specific individual claims or presentations are not misleading. FDA’s consideration of the net impression of risk information is based on well-developed social science principles supported by decades of scientific research and is consistent with the approach of other agencies and organizations. For example, the Federal Trade Commission (FTC) uses the interpretation of the net impression of the piece to determine whether a promotional piece is likely to mislead a consumer. P…

Open the original at page 7 on fda.gov ↗Read our full copy →

Document: FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: f5654ab082f6cd4408143f16…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The principle is well supported by the surrounding text: FDA 'looks not just at specific risk-related statements, but at the net impression - i.e., the message communicated by all elements of the piece as a whole', and 'Manufacturers should therefore focus not just on individual claims or presentations, but on the promotional piece as a whole.'
- But the rule as drafted overstates the quoted sentence in exactly the flagged way: the source says such a communication 'could be misleading', and the rule says the piece 'must not create a deceptive net impression'. 'Could be misleading' is not 'is prohibited', and this is a non-binding draft guidance.
- Atomic: a single net-impression assessment.
- Judgment determinism is correct — net impression is the paradigm case of an impression-based assessment.
- applies_when (promotional) matches the source's stated scope: 'Unless otherwise specified in this draft guidance, the principles set forth below apply to all promotional pieces, regardless of the medium used or the target audience.'
- Locator 'Section II.B, Policy Overview' is correct (the sentence closes the B. POLICY OVERVIEW discussion of net impression), authority 'guidance' is correct, and the check's instruction to read the whole piece as a reasonable audience member would is faithful to the source's approach.
- Severity 'warning' is on the low side for a deceptive net impression but is defensible given that the finding is a judgment about the piece as a whole rather than a discrete omission.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete sentence from Section II.B, and the rule keeps 'could be misleading' rather than 'is misleading'.
- The whole-piece evaluation clause is supported by the surrounding text ('Manufacturers should therefore focus not just on individual claims or presentations, but on the promotional piece as a whole'; 'whether the piece as a whole conveys an accurate and non-misleading impression of the benefits and risks'). It states how to judge the same requirement rather than adding a second one.
- The rule can be violated (a piece whose overall impression misleads), and it is not a restatement of a statute or regulation quoted in the guidance. Judgment determinism and the misleading-presentation category are appropriate.